This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Miller AH, Raison CL. Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies. Mol Psychiatry. 2022 https://doi.org/10.1038/S41380-022-01887-Y.
Abhyankar D. Ipilimumab: a tale of twists and turns. South Asian J Cancer. 2018;7:193.
Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133–50.
Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069–86.
Seligson ND, Knepper TC, Ragg S, Walko CM. Developing drugs for tissue‐agnostic indications: a paradigm shift in leveraging cancer biology for precision medicine. Clin Pharm Ther. 2021;109:334.
Photopoulos J. The future of tissue-agnostic drugs. Nature. 2020;585:S16–S18.
DeVita VT, Chu E. A history of cancer chemotherapy. Cancer Res. 2008;68:8643–53.
Dressel R, Greinix HT, Holler E, Dickinson AM. Editorial: Cellular therapies: past, present and future. Front Immunol. 2018;9:1966.
Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, et al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
le Rhun E, Preusser M, Roth P, Reardon DA, van den Bent M, Wen P, et al. Molecular targeted therapy of glioblastoma. Cancer Treatment Rev. 2019;80:101896.
Davola ME, Mossman KL. Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? 2019;8. https://doi.org/10.1080/2162402X.2019.1596006.
Zhang S, Rabkin SD. The discovery and development of oncolytic viruses: are they the future of cancer immunotherapy? 2020;16:391–410. https://doi.org/10.1080/17460441.2021.1850689.
Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28:844–51.
Farmer CA, Gilbert JR, Moaddel R, George J, Adeojo L, Lovett J, et al. Ketamine metabolites, clinical response, and gamma power in a randomized, placebo-controlled, crossover trial for treatment-resistant major depression. Neuropsychopharmacology. 2020;45:1398–404.
Center to Study Psychedelics for Treatment of Depression, Anxiety | Dell Medical School. https://dellmed.utexas.edu/news/dell-med-launches-center-to-study-psychedelics-for-treatment-of-depression-anxiety-ptsd.
Garber K. Delix therapeutics: psychedelics without the trip. Nat Biotechnol. 2022. https://doi.org/10.1038/D41587-022-00006-0.
Grunebaum MF, Mann JJ, Galfalvy HC, Gibbons RD. Computerized-adaptive vs. traditional ratings of depression and suicidal thoughts: an assay sensitivity pilot study in a ketamine clinical trial. Front Psychiatry. 2021;12:450.
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27:1025–33.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Jones, G., Machado-Vieira, R. The case for reverse engineering ketamine and psychedelics: lessons from translational oncology. A Response to Miller et al. “Burning down the house: reinventing drug discovery in psychiatry for the development of targeted therapies”. Mol Psychiatry (2023). https://doi.org/10.1038/s41380-023-02102-2
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41380-023-02102-2
This article is cited by
-
Psychedelics and ketamine are a symptom of psychiatry’s woes, not a cure
Molecular Psychiatry (2023)